Pricing Log in Create free account
Saturday 7 November 2026 Export PIII’s income statement to Excel — free account

P3 Health Partners Inc.

PIII Healthcare Medical Care Facilities

P3 Health Partners Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 2.76% from fiscal 2024.

Revenue
+8.60%
EPS
+89.9%
Free cash flow
−272.2%
Total debt
−34.1%

Quarter to June 2026, against a year earlier

4.05 0.23 +6.02%
Market cap
$28.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
2/9
Altman Z
−1.27
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.82
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — 1 — — —
Insider Ownership 41.40%

Capital & Financial Ratios $m

Size
Market Cap 28.13
Revenue ttm 1,502.84
Net income ttm (216.48)
Free cash flow ttm (130.52)
Net debt Q 98.08
Valuation
P/E 0.00
Forward P/E —
Price / sales 0.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 0.46 (below 1: weak)
Debt / equity Q 1.64
Interest coverage Q 5.24
Growth
Revenue growth Q +8.60% (above 0%: growing)
Operating income growth Q +220.81% (above 0%: growing)
EPS, this year +83.94% (at or above 15%: strong)
EPS, next year A −39.82% (below 0%: weak)
Revenue, next year A —
EPS, past 5 yrs —
EPS, next 5 yrs A +51.17% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.1×, against a ten-year median of 0.2×; over the ten years it ranged from 0.1× in 2024 to 22.9× in 2021.
P/S against its own 10 years 9.03%
10-year low 10-year high
EV/Sales against its own 10 years 3.53%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 41 44 26 22
Receivables 121 125 96 145
Inventory — — — —
Other — 0 — —
166 184 133 179
2023 2024 2025 Q'26
Payables 222 319 369 248
ST’ Debt — 75 45 22
Other 14 68 86 73
299 496 545 389

Compound Annual Growth %

10y 5y 3y
Sales — 24.33% 11.61%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY25 Estimate −3.29 Actual −6.23

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY24 −1.50 −15.50 Miss by 14.00
Q4 FY24 −8.50 −16.00 Miss by 7.50
Q1 FY25 −5.00 −6.28 Miss by 1.28
Q2 FY25 −3.29 −6.23 Miss by 2.94

EPS $

Mar Jun Sep Dec Year
’26 0.32 (0.63) — — —
’25 (6.28) (6.23) (9.67) (23.02) (45.26)
’24 (8.00) (7.37) (15.50) (18.00) (54.06)
’23 (11.00) (4.50) (6.00) (11.00) (31.50)
’22 (73.10) (186.55) (13.50) (113.01k) (325.00)
’21 0.12 (0.26) — (3.74) (12.12)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 386 386 — — —
’25 373 356 345 385 1,459
’24 388 379 362 371 1,500
’23 302 329 288 347 1,266
’22 274 269 248 258 1,049
’21 151 145 156 185 637
’20 — — — — 491
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (27) (62) — — —
’25 (33) (17) (15) (26) (91)
’24 (20) (10) (23) (57) (110)
’23 (24) (29) (8) (16) (76)
’22 (28) (45) (21) (32) (126)
’21 (13) (21) (6) (27) (66)
’20 — — — 0 (25)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (27) (62) — — —
’25 (33) (17) (16) (26) (91)
’24 (20) (10) (23) (57) (110)
’23 (24) (30) (8) (16) (78)
’22 (29) (46) (22) (32) (128)
’21 (14) (22) (7) (27) (70)
’20 — — — 0 (28)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 145 491 637 1,049 1,266 1,500 1,459 1,503 +46.9% — — — —
Gross margin, % — — — 3.06 1.34 (3.45) (0.74) 2.50 (3.93) (4.12) 4.70 (7.2) pt
EBT — — — (42) (31) (204) (1,560) (184) (306) (321) (227) +40.4%
EBT margin, % — — — (28.85) (6.40) (32.06) (148.62) (14.51) (20.39) (22.00) (15.12) +6.8 pt
Net income — 0 — (42) (31) (204) (1,562) (186) (310) (323) (216) n/m
Per share, $
Per share, $ Revenue — — — 0.00 12.28 766.43 1,261.99 667.29 516.69 446.34 447.01 n/m
Earnings — — — — — (12.12) (325.00) (30.50) (46.78) (45.26) (32.95) +39.0%
Cash flow — — — 0.00 (0.61) (79.93) (151.54) (40.06) (37.92) (27.91) (38.82) n/m
Capex — — — 0.00 (0.07) (4.10) (2.69) (0.96) 0.00 0.02 0.00 n/m
Free cash flow — — — 0.00 (0.69) (84.03) (154.22) (41.02) (37.92) (27.89) (38.82) n/m
Book value — — — 0.00 (3.26) 328.95 7.04 74.89 26.15 (47.49) 21.77 n/m
Shares, m — — — — 40 1 1 2 3 3 3 (39.4%)
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 0.00 0.00 22.96 0.07 0.12 0.02 0.01 0.01 3.3
P/B — — — 61.39 61.39 53.50 13.21 1.07 0.43 0.00 0.00 27.3
EV/Sales — — — 0.00 0.00 22.87 0.15 0.18 0.12 0.18 0.07 3.4
EV/FCF — — — 0.00 0.00 (208.62) (1.21) (2.85) (1.54) (2.84) (0.86) (31.0)
Cash, $m
Cash, $m Operating cash flow — — — (28) (25) (66) (126) (76) (110) (91) (131) +21.6%
Capex — — — (1) (3) (3) (2) (2) — 0 0 n/m
Free cash flow — — — (30) (28) (70) (128) (78) (110) (91) (131) +20.5%
Balance, $m
Balance, $m Working capital — — — — 0 1 (141) (133) (312) (412) (209) n/m
Net debt — — — — 6 (57) 78 67 140 248 98 +113.6%
Shareholders’ equity — — — — (130) 274 6 142 76 (155) 73 +3.6%
Returns, %
Returns, % ROA — — — 0.00 (59.02) (12.67) (16.67) (6.65) (16.52) (20.55) (15.59) (20.5) pt
ROIC — — — 0.00 0.00 (54.30) (1,163.92) (50.09) (92.83) (182.89) (54.24) (182.9) pt
ROE — — — 0.00 0.00 (218.34) (193.36) (78.08) (124.59) 373.15 461.69 +373.2 pt
People
People Employees — — — — 2 500 600 400 360 320 — +175.9%
Revenue/emp, $m — — — 0.00 245.53 1.27 1.75 3.17 4.17 4.56 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

P3 Health Partners Inc. vs peers in Medical Care Facilities (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
AIRS AirSculpt Technologies, Inc. $103.8M — (loss-making) — (loss-making) −8.71% (below 0%: shrinking) n/m −813.83% (below 0%: shrinking) 0.00% 0.00% Compare
PARK Park Dental Partners, Inc. $95.8M — (loss-making) — +12.15% (above 0%: growing) −65.84% (below 0%: shrinking) −34.78% (below 0%: shrinking) 14.37% 1.90% Compare
BMGL Basel Medical Group Ltd $70.5M — — — — — — — Compare
CCEL Cryo-Cell International Inc. $39.9M — (loss-making) 65.1× −0.02% (below 0%: shrinking) +77.78% (above 0%: growing) −58.37% (below 0%: shrinking) 79.38% 28.04% Compare
BTMD biote Corp. $37.4M 6.6× — (loss-making) −9.48% (below 0%: shrinking) n/m −174.16% (below 0%: shrinking) 65.38% (7.93%) Compare
PIII P3 Health Partners Inc. $28.1M — (loss-making) — +8.60% (above 0%: growing) n/m −272.24% (below 0%: shrinking) 22.26% 10.67%
DCGO DocGo Inc. $24.1M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −132.28% (below 0%: shrinking) 30.52% (24.41%) Compare
CCM Concord Medical Services Holdings Limited $10.0M — (loss-making) — (loss-making) +37.65% (above 0%: growing) n/m −281.45% (below 0%: shrinking) (13.15%) 0.00% Compare
AMS American Shared Hospital Services $7.8M — (loss-making) 1.8× +19.22% (above 0%: growing) n/m +195.82% (above 0%: growing) 17.00% (7.22%) Compare
Median of peers $38.6M — — −0.02% — −132.28% 17.00% 0.00%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 750.00k (1.09m) 3.79
2024 10.75m 4.36m 12.22
2023 1.37m 1.37m 76.63
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

P3 Health Partners Inc. (PIII) Latest News

22 Oct

Impact 3 · · Business Wire

12 Oct

Impact 3 · · Business Wire

17 Aug

Impact 3 · · The Motley Fool transcript

10 Aug

Impact 3 · · Moby transcript
Impact 3 · · MarketBeat
Impact 3 ·

27 Jun

Impact 4 ·

15 May

Impact 4 · · GuruFocus.com
Impact 4 ·
Impact 3 · · Moby transcript

14 May

Impact 4 · · Business Wire

26 Mar

Impact 4 · · Business Wire

8 Jan

Impact 4 ·

22 Dec

Impact 3 · · Simply Wall St.

8 Dec

Impact 4 ·

2 Dec

Impact 4 · · Business WireHospital ManagementStockStoryGuruFocus.comWealth ManagementMT NewswiresGuruFocus.comWealth Management

24 Nov

Impact 4 · · GuruFocus.com transcript
Impact 3 · · NewsfileMT NewswiresInsider MonkeyGuruFocus.comGuruFocus.comAssociated Press Finance

23 Nov

Impact 3 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

13 Nov

Impact 4 · · Business Wire

25 Aug

Impact 4 · · PR Newswire

16 Aug

Impact 3 ·

15 Aug

Impact 3 · · GuruFocus.com transcript

14 Aug

Impact 4 · · Business Wire
Impact 3 · · Zacks

29 May

Impact 3 · · TipRanks

28 Mar

Impact 4 · · GuruFocus.com

27 Mar

Impact 3 · · Business Wire

13 Mar

Impact 3 · · Business Wire

13 Feb

Impact 4 ·
stockrow.com/PIII · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com